(Q40100857)

17 September 2017

title

Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun (English)

1 reference

17 September 2017

0 references

Lactobacillus reuteri

object named as

Lactobacillus reuteri

1 reference

Yea Ping Lin

1

1 reference

17 September 2017

Carolyn H Thibodeaux

2

1 reference

17 September 2017

Jeremy A Peña

3

1 reference

17 September 2017

George D Ferry

4

1 reference

17 September 2017

James Versalovic

5

1 reference

17 September 2017

publication date

1 August 2008

1 reference

Inflammatory Bowel Diseases

17 September 2017

published in

1 reference

17 September 2017

volume

14

1 reference

17 September 2017

issue

8

1 reference

17 September 2017

page(s)

1068-1083

1 reference

Risk factors for initial surgery in pediatric patients with Crohn's disease.

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Tumor necrosis factor: biology and therapeutic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Adsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Chemokines in the inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

NF-κB-mediated repression of growth arrest- and DNA-damage-inducible proteins 45α and γ is essential for cancer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Use of complementary and alternative medicine in Germany - a survey of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Patterns of complementary and alternative medicine use in a population of pediatric patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Review article: treatment of mild to moderate ulcerative colitis and pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Probiotics in the treatment of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Use of probiotics in children with acute diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Probiotics and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Lactobacillus GG in inducing and maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Correlation between a gene polymorphism of tumor necrosis factor and inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

LPS induction of gene expression in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells: the role of the chromatin structure and AP-1 composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

TNFα as Therapeutic Target: New Drugs, More Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

The bacterial protein YopJ abrogates multiple signal transduction pathways that converge on the transcription factor CREB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppression of TNF production in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

Infliximab in pediatric ulcerative colitis: two-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIBD.20448

21 January 2018

Identifiers

DOI

10.1002/IBD.20448

1 reference

17 September 2017

1 reference